Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Guangxi Wehand-Bio Pharmaceutical Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, FIEBIG, RUSSELL G. As the only examiner listed, FIEBIG, RUSSELL G is also the busiest examiner, holding 1 busiest examiner pending action. The prosecution is focused within 1 distinct art unit, reflecting a concentrated effort by the company within a specific segment of the Biotechnology & Pharmaceuticals field.
The legal strategy for this portfolio is simplified by the presence of only 1 pending office action and 1 distinct examiner. Practitioners can focus their communication and arguments solely on FIEBIG, RUSSELL G without the need to coordinate across multiple examiners or art units. This 1:1 relationship between the 1 pending office action and the 1 distinct examiner in 1 distinct art unit minimizes administrative complexity. The focus on Biotechnology & Pharmaceuticals is handled through a single point of contact, which can lead to a more consistent prosecution experience for the 1 busiest examiner pending action. This high level of concentration in 1 distinct art unit suggests a very targeted intellectual property strategy for the current pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18804322 | Use of Extract from Morus alba L. in the Preparation of a Medicament for Preventing and/or Treating a Hepatobiliary Disease | FIEBIG, RUSSELL G | 12d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18804322 | Use of Extract from Morus alba L. in the Preparation of a Medicament for Preventing and/or Treating a Hepatobiliary Disease | FIEBIG, RUSSELL G | 1655 | §103 | Non-Final OA | 12d | Pending | Aug 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial